Osteoblast-specific mitogens and drugs containing such compounds

US6197759A · kind A · utility

Assignee

• Roche Diagnostics GMBH · DE

Inventors

• Angelika Esswein · Büttelborn, DE
• Lothar Kling · Mannheim, DE

Key dates

• Filing date: Apr 11, 2000
• Grant date: Mar 6, 2001
• Expiry date: Apr 11, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P19/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Osteoblast-specific mitogens and drugs containing such compounds can be used for treating metabolic bone diseases. These compounds include lysophosphatidylic acid derivatives selected from the group consisting of compounds of formula: ##STR1## wherein PA1 R.sup.1 =alkenyl or alkynyl having from 6 to 24 carbon atoms; PA1 n=0-12; PA1 X=oxygen or NH; the compounds (all-cis-5,8,11,14)-eicosatetraenoic acid 2-hydroxy-3-phosphonooxypropyl ester; cis-9, cis-12-octadecadienoic acid 2-hydroxy-3-phosphonooxypropyl ester; (all-cis-9,12,15)-octadecatrienoic acid 2-hydroxy-3-phosphonooxypropyl ester; cis-9-octadecenoic acid 2-hydroxy-3-phosphonooxypropyl ester; and erucic acid 2-hydroxy-3-phosphonooxypropylester being excluded, and the physiologically tolerable salts, esters, optically active forms, and racemates of said compounds, and derivatives of said compounds, salts, esters, optically active forms and racemates which can be metabolized in vivo to yield the corresponding compound of formula (I).